The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma. Dr Beksac mentions development strategies at the production level, as well as the addition of other agents to enhance responses to CAR-T. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So there’s a lot going on in the CAR-T field. We just recently published a review on the newer developments in the CAR-T field and that was published in the Balkan Medical Journal, which is a Q1 journal, and there we try to summarize the development strategies because there are now currently five generations of CAR-T’s and the newer ones, they are either humanized, they may have more than one epitope and they may target more than one antigen, and also it’s also possible that the production will be faster and that way the patients may have access to the CAR T quicker...
So there’s a lot going on in the CAR-T field. We just recently published a review on the newer developments in the CAR-T field and that was published in the Balkan Medical Journal, which is a Q1 journal, and there we try to summarize the development strategies because there are now currently five generations of CAR-T’s and the newer ones, they are either humanized, they may have more than one epitope and they may target more than one antigen, and also it’s also possible that the production will be faster and that way the patients may have access to the CAR T quicker. And these are all strategies at the production level to improve CAR-T efficacy. But on the other hand, we have been hearing today also at the IMS Congress that you can add additional drugs to enhance immune responsiveness to CAR-T and also to decrease T-cell exhaustion and amplify the T-cell reactions. So these are possible with the addition of IMiDs, CELMoDs and protein degraders. And these are the tools that can be used. And also, in addition, the BCMA antigen, which is shed into the circulation, that can be prevented by use of gamma-secretase inhibitors, which are now gaining importance. And these are the things that can be used to enhance CAR T-cell efficacy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Janssen: Research Funding, Speakers Bureau; Menarini: Consultancy, Other: advisory; GSK: Research Funding; Sanofi: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Amgen: Speakers Bureau; Takeda: Membership on an entity’s Board of Directors or advisory committees.
